Drugs / LPV/r
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00627055 | May 2008 → Nov 2010 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPV/r | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00627055 ↗ |
| Action | Inhibit | “ritonavir (RTV), known to boost the other protease plasma levels through potent inhibition of the cytochrome P450.” NCT00627055 ↗ |
| Route | Oral | “LPV/r dosing = 400mg/100mg orally q12h for 48 weeks” NCT00627055 ↗ |